Fierce Biotech News & Reports
3 天之前 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
2024年10月16日 · Novocure submitted Optune Lua for FDA review in NSCLC in December 2023, after also seeking a CE Mark approval in Europe. Around the same time—and following the field’s failure in a phase 3 ...
Notable goes bankrupt, ending plans for Boehringer cancer drug
2024年10月15日 · Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.. Notable's ...
Introducing Fierce Biotech's 2024 Fierce 15
One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...
Fierce Biotech Layoff Tracker 2024
March—18 companies. March 29 - Mustang Bio: Cell therapy-focused Mustang has laid off an undisclosed number of workers. The company declined to disclose how many employees would be impacted ...
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
2024年10月29日 · Novartis’ 2.7 billion euro ($2.9 billion) gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set back plans to seek ...
Vertex pain data: Combo results, Vicodin miss and stellar safety
2024年10月21日 · Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...
Cour inks $940M-plus autoimmune deal with Roche's Genentech
2024年12月3日 · Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission to the fore with a new deal featuring Swiss drug juggernaut Roche.
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
2024年3月19日 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for chronic weight ...
Roche inks $1.5B Poseida buyout to land off-the-shelf CAR-Ts
2024年11月26日 · Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which Roche has said can democratize CAR-Ts, as a new core capability at ...